A Nonparametric Population Pharmacokinetic Model of Selumetinib in Pediatric Patients Diagnosed With Neurofibromatosis‐I or Plexiform Neurofibromas

ABSTRACT A twice‐daily administration of oral selumetinib (SLT) in the fasted state is the only approved pharmaceutical option for treating inoperable neurofibromatosis type I (NF‐1) and plexiform neurofibromas (PN). In children, exposure to SLT is highly variable, and fasting presents a substantial...

Descripció completa

Dades bibliogràfiques

Autors principals:	Zoltán Köllő, Janka Kovács, Michael N. Neely, Barna Vásárhelyi, Edit Brückner, Attila J. Szabo, Miklós Garami, Gellért Balázs Karvaly
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2026-01-01
Col·lecció:	CPT: Pharmacometrics & Systems Pharmacology
Matèries:	oncology personalized medicine pharmacometrics population pharmacokinetics
Accés en línia:	https://doi.org/10.1002/psp4.70156
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!